Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.04.2015 | short review | Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015

A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma

memo - Magazine of European Medical Oncology > Ausgabe 1/2015
MD Bahil Ghanim, MD Mir Alireza Hoda, MD Thomas Klikovits, MD, PhD Balazs Dome, PhD Michael Grusch, PhD Martin Filipits, MD Walter Klepetko, PhD Walter Berger, PhD Balazs Hegedus
Wichtige Hinweise
Part of this manuscript has been presented by Bahil Ghanim at the 11th “PneumoUpdate” (12th to 14th June 2014, Igls, Tyrol, Austria).


Malignant pleural mesothelioma (MPM) is a devastating and treatment-resistant disease. Currently, well-established prognostic and predictive biomarkers are rare in clinical practice, whereas there is a whole body of various MPM biomarker studies published in medical literature in the past decades. Besides well-established pathological parameters, including histological subtype, disease stage, or level of lymph node involvement, blood parameters and circulating proteins related to a proinflammatory phenotype are emerging as prognostic biomarkers. Here we provide an overview about the current status of prognostic and predictive biomarkers in MPM, with a strong emphasis on their applicability in clinical practice.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe